SCHEMBL16711902

SCHEMBL16711902

CC(C)C(Oc1ccc(-n2cccn2)c(F)c1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 7/20 0.43
CYP2C8 P10632 2/20 0.43
CYP2C9 P11712 2/20 0.43
ACLY P53396 1/20 0.41
PTGDR Q13258 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
KCNN4 O15554 1/20 0.37
KCNA5 P22460 1/20 0.37
KAT6A Q92794 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
G6PD P11413 1/20 0.37
CYP1A2 P05177 1/20 0.37
USP9X Q93008 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16712132 0.86 KCNH2 (0.39) KCNH2CYP2C8CYP2C9ACLYPTGDR
SCHEMBL27769009 0.80 CRHR1 (0.40) KCNH2CYP2C8CYP2C9ACLYALDH1A1
SCHEMBL16712122 0.73 PDE2A (0.41) KCNH2CYP2C8CYP2C9MEN1KMT2A
SCHEMBL22187765 0.72 MAPT (0.42) KCNH2CYP2C8CYP2C9ACLYALDH1A1
SCHEMBL21057173 0.71 SLC6A4 (0.47) CYP2C9ALDH1A1KMT2APPARGPPARA
SCHEMBL21057171 0.71 SLC6A4 (0.47) CYP2C9ALDH1A1KMT2APPARGPPARA
SCHEMBL23368023 0.70 ALDH1A1 (0.53) CYP2C9ALDH1A1MAPTKMT2APPARG
SCHEMBL31709885 0.70 KCNH2 (0.49) KCNH2CYP2C8CYP2C9ACLYALDH1A1
SCHEMBL7031591 0.70 ALDH1A1 (0.46) ACLYALDH1A1MEN1MAPTKMT2A
SCHEMBL31710093 0.70 ALDH1A1 (0.55) ACLYALDH1A1MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9527841-B2 Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20150158863-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-06-11 US disclosed
EP-2873669-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158863-A1 HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A KCNH2 845/4885CYP2C8 2246/4885CYP2C9 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.